Read more
This book provides a detailed review of the most recent pathogenetic, diagnostic and therapeutic approaches in connection with Helicobacter pylori, along with priority areas in research and trends in clinical practice to address this significant pathogen acknowledged as the causative agent in a wide range of diseases, including gastric adenocarcinoma, MALT lymphoma and immune thrombocytopenic purpura (ITP). Medical authorities worldwide now recommend a "test and treat" strategy for this bacterial infection. Eradication therapy approaches range from general mass eradication therapy to tailor-made therapy for antibiotic-resistant refractory infection. In regions with high prevalence of H. pylori infection, the infection itself would be considered a major parameter to predict the risk of gastric adenocarcinoma development. The main interest has shifted recently to the risk stratification strategy for gastric cancer development and to the wide-ranging application of its serological prevention program.
This book will benefit all gastroenterologists, hematologists, dermatologists, primary care doctors, epidemiologists, physicians who related with community hygiene, as well as basic scientists, particularly microbiologists, bacteriologists, pathologists, molecular biologists, biochemists, immunologists and oncologists.
List of contents
Part I History.- Chapter 1 Brief History of the Discovery of Helicobacter Pylori.- Part II Pathogenesis.- Chapter 2 Human Migration.- Chapter 3 CagA.- Chapter 4 Helicobacter Pylori VacA Exhibits Pleiotropic Actions in Host Cells.- Chapter 5 Autophagy.- Chapter 6 Ghrelin and Gut Hormone.- Chapter 7 Symptom Generation.- Chapter 8 Gastric Non-Helicobacter Pylori Helicobacter: It's Significance in Human Gastric Diseases.- Part III Diagnosis.- Chapter 9 Urea Breath Test & Rapid Urease Test.- Chapter 10 Endoscopic Findings of H. Pylori Infection.- Chapter 11 Gastric Cancer Risk stratification by H. pylori.- Chapter 12 Prevention of Gastric Cancer by Helicobacter Pylori Eradication: Current Evidence and Future Prospects.- Part IV Treatment.- Chapter 13 Trends in Global Eradication Rates.- Chapter 14 Personalized Therapy in H. Pylori Eradication.- Chapter 15 Quadruple Regimens for Helicobacter Pylori Infection.- Chapter 16 Third-Line Eradication Therapy
About the author
Dr Hidekazu Suzuki,
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Dr Robin Warren,
A winner of the 2005 Nobel Prize winner in Physiology or Medicine
Emeritus Professor at the University of Western Australia and the Royal Perth Hospital, Australia
Dr Barry Marshall,
A winner of the 2005 Nobel Prize winner in Physiology or Medicine
Marshall Centre for Infectious Diseases Research and Training, School of Pathology and Laboratory Medicine, The University of Western Australia, Australia
Summary
This book provides a detailed review of the most recent pathogenetic, diagnostic and therapeutic approaches in connection with Helicobacter pylori, along with priority areas in research and trends in clinical practice to address this significant pathogen acknowledged as the causative agent in a wide range of diseases, including gastric adenocarcinoma, MALT lymphoma and immune thrombocytopenic purpura (ITP). Medical authorities worldwide now recommend a “test and treat” strategy for this bacterial infection. Eradication therapy approaches range from general mass eradication therapy to tailor-made therapy for antibiotic-resistant refractory infection. In regions with high prevalence of H. pylori infection, the infection itself would be considered a major parameter to predict the risk of gastric adenocarcinoma development. The main interest has shifted recently to the risk stratification strategy for gastric cancer development and to the wide-ranging application of its serological prevention program.
This book will benefit all gastroenterologists, hematologists, dermatologists, primary care doctors, epidemiologists, physicians who related with community hygiene, as well as basic scientists, particularly microbiologists, bacteriologists, pathologists, molecular biologists, biochemists, immunologists and oncologists.
